EIKN compared with AKTS: revenue, margins and what each company keeps, and the suppliers and customers both name

EIKNEikon Therapeutics, Inc.

Mkt capRevenueRevenue

AKTSAktis Oncology, Inc.

Mkt capRevenueRevenue

Compare

EIKNEikon Therapeutics, Inc.

AKTSAktis Oncology, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

EIKN1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+6.97%—

AKTS3 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±17.0%▲+4.79%×0.28

May 12 '26—▲+7.99%—

= impliedEIKN realized, solidAKTS realized, hatchedOne scale, both sides: full bar = 17%× = |realized| ÷ impliedSource: market data

Q1 FY26—▲+8.16%—

EIKNEikon Therapeutics, Inc.

5.68· pre 5.66· delayed

Mkt cap$287.5MRevenue—

AKTSAktis Oncology, Inc.

14.58· pre 14.85· delayed

Pre-marketNov 3 '26delayed

Mkt cap$806.8MRevenue$3MQ2 FY26

Compare

Pre-marketNov 3 '26delayed

EIKNEikon Therapeutics, Inc.

AKTSAktis Oncology, Inc.

5.68pre 5.66delayed

Price

14.58pre 14.85delayed

$287.5M

Mkt cap

$806.8M

—

Revenue

$3MQ2 FY26

EIKN5.68vsAKTS14.58Pre-marketNov 3 '26delayed